Mackay Shields LLC’s Bio-Rad Laboratories Class A BIO Stock Holding History

Mackay Shields LLC’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,138	Closed	-$1.77M	–	300
2022 Q1	$1.77M	Sell	3,138 -127	-4%	-$76.6K	0.02%	580
2021 Q4	$2.47M	Sell	3,265 -70	-2%	-$52.4K	0.02%	526
2021 Q3	$2.49M	Sell	3,335 -96	-3%	-$71.9K	0.02%	500
2021 Q2	$2.21M	Sell	3,431 -287	-8%	-$175K	0.02%	521
2021 Q1	$2.12M	Sell	3,718 -21	-0.6%	-$12.4K	0.02%	748
2020 Q4	$2.18M	Sell	3,739 -550	-13%	-$313K	0.02%	821
2020 Q3	$2.21M	Buy	4,289 +221	+5%	+$112K	0.02%	745
2020 Q2	$1.84M	Buy	+4,068	New	+$1.8M	0.01%	792
2019 Q4	–	Sell	-1,946	Closed	-$648K	–	1356
2019 Q3	$648K	Buy	+1,946	New	+$635K	﹤0.01%	1211
2018 Q3	–	Sell	-2,661	Closed	-$768K	–	1156
2018 Q2	$768K	Sell	2,661 -10,681	-80%	-$2.95M	0.01%	1021
2018 Q1	$3.34M	Buy	+13,342	New	+$3.4M	0.02%	635

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackay Shields LLC's BIO Position: Q2 2022 in Review

Mackay Shields LLC sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 3,138 shares — an estimated $1.77M sold.

Mackay Shields LLC first reported a position in BIO in Q1 2018 and held it in 11 quarters. The position peaked at $3.34M in Q1 2018. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

Mackay Shields LLC reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
Mackay Shields LLC sold 3,138 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $1.77M.
Mackay Shields LLC first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and held it in 11 quarters.
Mackay Shields LLC's Bio-Rad Laboratories Class A position peaked at $3.34M in Q1 2018.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Mackay Shields LLC's 13F filing for Q2 2022, filed 3 Aug 2022.